NCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
Conjupro Biotherapeutics, Inc.
University of Chicago
Gustave Roussy, Cancer Campus, Grand Paris
Pfizer